Gastrointestinal Drugs Advisory Committee; Cancellation, 27072 [2012-10990]
Download as PDF
<![CDATA[
27072
Federal Register / Vol. 77, No. 89 / Tuesday, May 8, 2012 / Notices
subsequent 60 day notices for later
components of the evaluation. The first
phase includes data collection for a
cross-site implementation study and
site-specific impact evaluations in two
PIT grantee sites (Kansas; Washoe
County, Nevada) that will begin
implementing interventions during the
second year of the PII grant period. The
second phase includes a cross-site cost
evaluation and site-specific impact
evaluations in four PII grantee sites
expected to implement interventions in
the third year of the PII grant period.
Data for the cross-site implementation
study will be collected through: (1)
Interviews with grantee staff and key
informants conducted by telephone and
during site visits; (2) web-based
instruments completed by grantee staff
and key informants; and (3) retrieval
and submission of aggregate data from
grantee data systems. Data for the
Kansas impact evaluation will be
collected through (1) family
assessments; (2) caseworkers’ clinical
assessments of children and families;
and (3) caseworker discussions. Data for
the Washoe County impact evaluation
will be collected through family
assessments.
Respondents: Families (parents, or
permanent or foster caregivers;
children), caseworkers, supervisors,
service providers, and key informants
such as grantee project directors, data
managers, and representatives of partner
agencies.
ANNUAL BURDEN ESTIMATES
Annual
number of respondents
Instrument
Number of
responses per
respondent
60
150
30
2
—
1
2
4
8
—
0.3
0.8
2.0
1.5
—
18
240
240
24
522
300
300
4
4
—
1
3
150
150
—
0.1
1.5
1.0
0.5
—
30
1350
600
300
2280
175
—
2
—
1.5
—
525
525
srobinson on DSK4SPTVN1PROD with NOTICES
CROSS-SITE IMPLEMENTATION STUDY:
Survey of Organization/System Readiness .....................................................
Implementation Drivers Web Survey ...............................................................
Grantee Case Study Protocol ..........................................................................
Fidelity Data (Implementation Quotient Tracker) .............................................
Cross-Site Estimated Total ..............................................................................
KANSAS:
Caregiver Initial Information Form ............................................................
Family Assessment Battery ......................................................................
CAFAS/PECFAS ......................................................................................
Caseworker Discussions for NCFAS–G&R Completion ..................................
Kansas Estimated Total ...................................................................................
WASHOE COUNTY:
Family Assessment Battery ......................................................................
Washoe Estimated Total ..........................................................................
Estimated Total Annual Burden
Hours: 3327.
Additional Information: Copies of the
proposed collection may be obtained by
writing to the Administration for
Children and Families, Office of
Planning, Research and Evaluation, 370
L’Enfant Promenade SW., Washington,
DC 20447, Attn: OPRE Reports
Clearance Officer. All requests should
be identified by the title of the
information collection. Email address:
OPREinfocollection@acf.hhs.gov.
OMB Comment: OMB is required to
make a decision concerning the
collection of information between 30
and 60 days after publication of this
document in the Federal Register.
Therefore, a comment is best assured of
having its full effect if OMB receives it
within 30 days of publication. Written
comments and recommendations for the
proposed information collection should
be sent directly to the following: Office
of Management and Budget, Paperwork
Reduction Project, Email:
OIRA_SUBMISSION@OMB.EOP.GOV,
Attn: Desk Officer for the
VerDate Mar<15>2010
17:33 May 07, 2012
Jkt 226001
Administration, for Children and
Families.
Steven M. Hanmer,
OPRE Reports Clearance Officer.
[FR Doc. 2012–10848 Filed 5–7–12; 8:45 am]
BILLING CODE 4184–01–M
Average
burden hours
per response
Total annual
burden hours
information which negated the necessity
for the planned meeting. The Agency
intends to continue evaluating NDA
200–436 and, as needed, may schedule
an Advisory Committee meeting in the
future.
FOR FURTHER INFORMATION CONTACT:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2012–N–0001]
Gastrointestinal Drugs Advisory
Committee; Cancellation
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The meeting of the
Gastrointestinal Drugs Advisory
Committee scheduled for May 31, 2012,
is canceled. This meeting was
announced in the Federal Register of
March 23, 2012 (77 FR 17078). The
meeting is being canceled because the
Agency no longer needs to discuss the
issues that were originally under
consideration in the review of the
application. The sponsor of the new
drug application (NDA) submitted new
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 9990
Minh Doan, Center for Drug Evaluation
and Research, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 31, rm. 2417, Silver Spring,
MD 20993–0002, 301–796–9001, Fax:
301–847–8533, email:
GIDAC@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1–800–
741–8138 (301–443–0572 in the
Washington, DC area), to find out
further information regarding FDA
advisory committee information or visit
our Web site at https://www.fda.gov/
AdvisoryCommittees/default.htm.
Dated: May 2, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2012–10990 Filed 5–7–12; 8:45 am]
BILLING CODE 4160–01–P
E:\FR\FM\08MYN1.SGM
08MYN1
]]>Agencies
[Federal Register Volume 77, Number 89 (Tuesday, May 8, 2012)]
[Notices]
[Page 27072]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-10990]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2012-N-0001]
Gastrointestinal Drugs Advisory Committee; Cancellation
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The meeting of the Gastrointestinal Drugs Advisory Committee
scheduled for May 31, 2012, is canceled. This meeting was announced in
the Federal Register of March 23, 2012 (77 FR 17078). The meeting is
being canceled because the Agency no longer needs to discuss the issues
that were originally under consideration in the review of the
application. The sponsor of the new drug application (NDA) submitted
new information which negated the necessity for the planned meeting.
The Agency intends to continue evaluating NDA 200-436 and, as needed,
may schedule an Advisory Committee meeting in the future.
FOR FURTHER INFORMATION CONTACT: Minh Doan, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax:
301-847-8533, email: GIDAC@fda.hhs.gov, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), to find out further information regarding FDA advisory committee
information or visit our Web site at https://www.fda.gov/AdvisoryCommittees/default.htm.
Dated: May 2, 2012.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2012-10990 Filed 5-7-12; 8:45 am]
BILLING CODE 4160-01-P
